BRIEF-Novavax Initiates Covid-19 Vaccine Clinical Trial Crossover

PUBLISHED: Mon, 05 Apr 2021 20:08:48 GMT
Share

April 5 (Reuters) – Novavax Inc:

* NOVAVAX INITIATES COVID-19 VACCINE CLINICAL TRIAL CROSSOVER

* NOVAVAX INC – CROSSOVER ALLOWS PARTICIPANTS TO CONTINUE IN TRIALS AND REMAIN BLINDED

* NOVAVAX INC – CROSSOVER ENSURES THAT ALL TRIAL PARTICIPANTS RECEIVE ACTIVE VACCINE

* NOVAVAX INC – SOUTH AFRICA AND UK CROSSOVER ARMS INITIATED; US/MEXICO PREVENT-19 CROSSOVER PLANNED

* NOVAVAX INC – ALL PARTICIPANTS IN UK AND U.S. PHASE 3 TRIALS WILL BE OFFERED OPPORTUNITY TO RECEIVE AN ADDITIONAL ROUND OF INJECTIONS

* NOVAVAX – PLANNING TO EXPAND TRIAL TO INCLUDE PEDIATRIC AND ADOLESCENT ARMS, WHICH ARE ALSO EXPECTED TO BEGIN IN Q2

* NOVAVAX INC – COMPANY IS ALSO PLANNING A CROSSOVER IN PREVENT-19 STUDY, FOR WHICH COMPANY EXPECTS TO READ OUT INITIAL CLINICAL DATA DURING Q2 Source text for Eikon: Further company coverage:

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.